Recipharm, has announced a $3m investment for additional manufacturing capacity at its Kaysersberg facility.
This latest investment is part of a phased expansion plan for the facility. Yves Buelens, General Manager at the Kaysersberg facility, said: “It’s great to see more investment into our facility. Our sustained growth over the last few years is testament to our talented and passionate team. We continue to look for new ways to develop our offering and implement our continued growth plan, which will naturally bring more employment opportunities to the region.”
The Kaysersberg location is one of the company’s sterile manufacturing facilities. It specialises in producing sterile liquids for therapeutic areas including eye care and ear drops.
The facility has been inspected and approved by regulatory agencies across the globe. It also holds a number of approvals for its environmental management systems and occupational health and safety management systems.
